LFG
RXRX icon

Larson Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Larson Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54K Hold
501
– – ﹤0.01% 3034
2025
Q4 		$2.05K Buy
501
+496
+9,920% +$2.46K ﹤0.01% 2779
2025
Q3 		$24 Buy
+5
New +$26 ﹤0.01% 3388
2024
Q4 		– Sell
-207
Closed -$1.36K – 2885
2024
Q3 		$1.36K Sell
207
-101
-33% -$724 ﹤0.01% 1922
2024
Q2 		$2.31K Buy
308
+199
+183% +$1.74K ﹤0.01% 1575
2024
Q1 		$1.09K Buy
+109
New +$1.21K ﹤0.01% 1438

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Larson Financial Group's RXRX Position: Q1 2026 in Review

Larson Financial Group held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 501 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3034.

Larson Financial Group first reported a position in RXRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.31K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Larson Financial Group held 501 shares of Recursion Pharmaceuticals worth $1.54K as of Q1 2026.
  • Larson Financial Group left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3034 holding.
  • Larson Financial Group first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Larson Financial Group's Recursion Pharmaceuticals position peaked at $2.31K in Q2 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.